Clinical and Diagnostic Laboratory Immunology, May 1999, p. 425-426, Vol. 6, No. 3
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Identification of a Peptide from Mammal Albumins Responsible for
Enhanced Pigment Production by Group B Streptococci
Manuel
Rosa-Fraile,1,*
Antonio
Sampedro,1
Javier
Varela,2
Marisa
Garcia-Peña,1 and
Guillermo
Gimenez-Gallego2
Microbiology Service, Virgen de las Nieves
Hospital, 18014 Granada,1 and Centro
de Investigaciones Biologicas, Consejo Superior de
Investigaciones Cientificas, 28006 Madrid,2
Spain
Received 3 August 1998/Returned for modification 2 December
1998/Accepted 19 January 1999
 |
ABSTRACT |
The peptide from peptones responsible for enhanced pigment
production by Streptococcus agalactiae in culture media has
been isolated from a peptic digest of human albumin and has been
identified as Ile-Ala-Arg-Arg-His-Pro-Tyr-Phe. The related heptapeptide
lacking the N-terminal Ile also had pigment-enhancing activity. A
sequence similarity search showed that these sequences are present only in mammal albumins.
 |
TEXT |
Streptococcus agalactiae
(group B streptococcus [GBS]) is an important cause of infections in
newborns and adults (18, 21). Human beta-hemolytic GBS
produce an orange or red pigment that can be detected on
certain culture media (4, 8). This method is very specific
and can be used to detect and identify GBS (1, 9a). Peptone
(8), starch (5, 8, 13, 20), folate pathway inhibitors (3), and serum
(8) are important components of culture media for
pigment detection of GBS. Some peptones, such as proteose peptone
(PP) no. 3 (Difco, Detroit, Mich.), have pigment-enhancing (PE)
activity, and pigment production is poor when other peptones are used
(3, 8, 12, 20). The serum component that accounts for its PE
activity has been identified as amylase (15). However, the
active component of peptones had not been defined, and because this
knowledge could help improve the design of culture media
(19), we undertook this study to identify it. PE activity
was detected by bioautography (9, 14, 15). Two
beta-hemolytic GBS strains were used; one was isolated from a patient
and identified by accepted procedures (9a, 16), and the
other was S. agalactiae ATCC 13813. The test medium was New
Granada Medium (4) in which PP from Oxoid (Basingstoke,
United Kingdom) was substituted for PP no. 3. This medium also
contained serum, starch, methotrexate, glucose, and a
morpholinepropanesulfonic acid (MOPS)-phosphate buffer. Previous experiments had shown that in this medium GBS pigment production was
poor. Twelve milliliters of medium (at 50°C) was poured into 9.5-cm-diameter petri dishes, mixed with 20 µl of an overnight culture of the test strain in brain heart infusion broth, and left to
solidify. In each plate, 7-mm-diameter wells were cut and filled with
40 µl of each dilution of the fluid to be assayed in distilled water.
The plates were incubated under anaerobic conditions (85%
N2, 10% H2, and 5% CO2) for
18 h at 37°C, and a zone of orange-red GBS microcolonies formed
around the wells, showing PE activity. A unit of PE activity (PEU) was
defined as the activity present in the well with the highest dilution
of each biological fluid that showed activity. Protein levels were determined by the bicinchoninic acid procedure (kit from Pierce Biochemicals, Rockford, Ill.). The peptide concentration was determined by measuring the absorbance at either 280 or 215 nm (model 220S spectrophotometer; Hitachi, Tokyo, Japan). All chromatographic separations were done with a Pharmacia (Uppsala, Sweden) system (FPLC Controller LCC System 500 Plus). The protein concentration in
eluates was monitored by measuring the absorbance at either 280 or 214 nm (Uvicord II apparatus; Pharmacia). Chromatographic columns
were also from Pharmacia. Tris-Tricine-sodium dodecyl sulfate
polyacrylamide gel electrophoresis (17) was run in a Mini-Protean II cell (Bio-Rad Laboratories, Hercules, Calif.). Gels were stained with Coomassie brilliant blue. Molecular
weights were estimated with markers from Bio-Rad. Mass spectra were
acquired in a Bruker Biflex MALDI-TOF spectrometer by using
3,5-dimethoxy-4-hydroxycinnamic acid as an ionizing matrix. Protein
sequencing was carried out in a Procise microsequencer
(Perkin-Elmer-Applied Biosystems). Peptide synthesis was carried
out by following the manufacturer's protocols in a Synergy 432A
9-fluorenylmethoxycarbonyl synthesizer (Perkin-Elmer).
PE activity was detected in the Difco peptones PP no. 3 (0.001 PEU/µg), PP no. 2 (0.0005 PEU/µg), PP (0.0005 PEU/µg), and Peptamine (0.001 PEU/µg); in the Sheffield peptone (Quest, Norwich, N.Y.) Primatone RL (0.0005 PEU/µg); and in a peptone prepared by
hydrolyzing human serum with pepsin. However, activity was not detected
in any of the Difco products peptone, tryptone, tryptose, and Soytone;
in the Oxoid products PP, Lab Lemco, and lactoalbumin hydrolysate; in
the Sheffield products HY Soy, Primatone HS, N-Z Amine A, N-Z Amine E,
N-Z Amine HD, and Amisoy N-Z; or in peptones prepared by hydrolyzing
human serum with trypsin, ficin, or proteinase K.
When a PP no. 3 solution was ultrafiltered by using a membrane with a
molecular mass cutoff of 1,000 Da (Millipore Co., Bedford, Mass.)
activity could be recovered from the ultrafiltrate. However, this
ultrafiltrate lost its activity when hydrolyzed with trypsin. We
hypothesized that the active substance was a peptide. Owing to the
difficulty of characterization of active compounds in peptones (2, 19), we attempted to hydrolyze a protein of known
sequence, where activity could be detected, and to identify the active
peptide. We tested enzymatic digests (pepsin, trypsin, proteinase K,
and ficin) of several proteins (human and bovine albumin, ovalbumin, gamma globulin, cytochrome c, hemoglobin, myoglobin,
thyroglobulin, insulin,
-lactoglobulin, aprotinin, actin,
2-macroglobulin, ferritin, and
-amylase from hog and human
saliva). Activity was found only in peptic digests from human and
bovine albumin (0.04 PEU/µg). As the sequence of albumin is perfectly
known (11), we tried to identify the PE products from
pepsin-treated fragments of this protein. Hydrolysates were made with
hog pepsin (0.05 mg/mg of protein) at 50°C for 4 h, after the pH
was adjusted to 2.5 with HCl.
One gram of human albumin (99%, fatty acid and globulin free;
Sigma Chemical Co., St. Louis, Mo.) was cleaved with CNBr
(6), and the three fragments obtained (10) were
separated in two steps: (i) size exclusion chromatography in a
column (95 by 2.6 cm) of Sephacryl HR 100 (Pharmacia) with 50 mM formic
acid and (ii) application of the fraction with the lowest molecular
weight (two peptides) from step 1 to a 6-ml column of a strong cationic exchanger (Resource S; Pharmacia). One peptide was eluted with 25 mM
phosphate buffer (pH 6.7) and the other peptide was then eluted with
0.5 M NaCl. This second peptide is a 175-aa peptide (from Cys124
to Met298) (10). After pepsin hydrolysis, all the activity
was in this 175-aa peptide (0.1 PEU/µg). This peptide was
cleaved at its tryptophan (Try215) with dimethyl sulfoxide-CNBr (7). The products were dissolved in 6 M guanidine HCl-0.6 M Tris HCl (pH 8.5)-100 mM 2-mercaptoethanol and were separated (the
yield was about 50%) by size exclusion chromatography in a column of
Superdex 75 eluted with the same buffer. The two peptides (91 and 84 aa) from the cleavage of the 175-aa peptide were separated from each
other by reversed-phase chromatography with a Source 15 column
equilibrated with 0.1% trifluoroacetic acid (TFA) and eluted with a
linear gradient to 50% CH3CN-0.1% TFA. After pepsin hydrolysis of each of these two separated peptides the activity was in
the 91-aa peptide (from Cys124 to Trp214) (0.2 PEU/µg). This peptide
was hydrolyzed with immobilized pepsin (Sigma). Afterward, the products
from this hydrolysis were separated by reversed-phase chromatography
with a PEP 5/5 column equilibrated with 0.1% TFA and eluted with
a linear gradient to 17% CH3CN-0.1% TFA. Activity was detected only in a single peak that was resolved in four peaks by
size exclusion chromatography in a Superdex peptide column eluted with
20% CH3CN-0.1% TFA. Activity was detected only in the
first of these peaks (0.5 PEU/µg). Sequencing showed that this peak
was a mixture of two peptides: Ile-Ala-Arg-Arg-His-Pro-Tyr-Phe (albumin
positions 142 to 149) and Phe-Ala-Lys-Arg-Tyr-Lis-Ala-Ala-Phe (albumin
positions 157 to 165).
These peptides were synthesized, and only
Ile-Ala-Arg-Arg-His-Pro-Tyr-Phe was active (2 PEU/µg). However, the
activity of this peptide was lost when the peptide was hydrolyzed with
trypsin. Afterward, the peptides
Ala-Arg-Arg-His-Pro-Tyr-Phe, Ile-Ala-Arg-Arg-His-Pro-Tyr, Ala-Arg-Arg-His-Pro-Tyr, Ile-Ala-Arg-Arg-His-Pro, and
Arg-Arg-His-Pro-Tyr-Phe were synthesized; only the heptapeptide
Ala-Arg-Arg-His-Pro-Tyr-Phe showed activity (2 PEU/µg). A
search in the molecular biology server of the Swiss Institute of
Bioinformatic (13a) showed that the amino acid pattern
Ala-Arg-Arg-His-Pro-Tyr-Phe matched only with mammal albumins and with
the albumin-derived peptide kinetensin.
This suggests that some peptones show PE activity because they are
peptic digests of protein mixtures that contain albumin and so contain
the peptide Ile-Ala-Arg-Arg-His-Pro-Tyr-Phe. This would account for the
different abilities of commercial peptones to support the growth of GBS
as pigmented colonies. In addition, this finding would also allow
minimization of the variability in pigment production associated with
the different types of peptones used in culture media for the detection
of GBS pigment.
How these peptides cause their PE activity is not clear, and further
investigation is necessary. Investigating specific activities in very
complex mixtures of biological compounds, such as peptones, can be a
very difficult task. However, the approach outlined in this work of
using a defined starting product that leads to defined end products
could be worthwhile in trying to solve similar problems.
 |
ACKNOWLEDGMENTS |
This work was supported by a grant from the FIS, Spanish Ministry
of Health (Project 95/0984) and by a grant from the Andalusian Regional
Government (Consejeria de Salud).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Servicio de
Microbiología, Hospital Virgen de las Nieves, 18014 Granada,
Spain. Phone: 34-958-241109. Fax: 34-958-241282 or 34-958-241245. E-mail: delarosa{at}cica.es.
 |
REFERENCES |
| 1.
|
Boyd, R. F.
1995.
Basic medical microbiology, 5th ed., p. 256.
Little, Brown & Co., Boston, Mass.
|
| 2.
|
Bridson, E. Y.
1978.
Natural and synthetic culture media for bacteria, p. 91-282.
In
M. Rechcigl, Jr. (ed.), CRC handbook series in nutrition and food, section G. Diets, culture, media, and food supplements. CRC Press, Inc., Cleveland, Ohio.
|
| 3.
|
De La Rosa, M.,
D. Villareal,
D. Vega,
C. Miranda, and A. Martinez-brocal.
1983.
Granada medium for detection and identification of group B streptococci.
J. Clin. Microbiol.
18:779-785[Abstract/Free Full Text].
|
| 4.
|
de la Rosa, M.,
M. Perez,
C. Carazo,
L. Pareja,
J. I. Peis, and F. Hernandez.
1992.
New Granada Medium for detection and identification of group B streptococci.
J. Clin. Microbiol.
30:1019-1021[Abstract/Free Full Text].
|
| 5.
|
Fallon, R. J.
1974.
The rapid recognition of Lancefield group B haemolytic streptococci.
J. Clin. Pathol.
27:902-905[Abstract/Free Full Text].
|
| 6.
|
Gros, E.
1967.
The cyanogen bromide reaction.
Methods Enzymol.
11:238-253.
|
| 7.
|
Huang, H. V.,
M. W. Bomd,
M. W. Hunkapiller, and L. Hood.
1983.
Cleavage of tryptophanyl residues with dimethyl sulfoxide hydrochloric acid and cyanogen bromide.
Methods Enzymol.
91:318-323[Medline].
|
| 8.
|
Islam, A. K. M.
1977.
Rapid recognition of group B streptococci.
Lancet
i:256-257.
|
| 9.
|
Kennedy, H. E.,
M. L. Speck, and L. W. Aurand.
1955.
Studies on a growth stimulant from corn steep using Lactobacillus casei.
J. Bacteriol.
70:70-77[Free Full Text].
|
| 9a.
|
Koneman, E. W.,
D. D. Allen,
W. M. Janda,
P. C. Schreckenberger, and W. C. Winn (ed.).
1997.
Color atlas and textbook of diagnostic microbiology, 5th ed., p. 608.
Lippincott, Philadelphia, Pa.
|
| 10.
|
McMenamy, R. H.,
H. M. Dintzis, and F. Watson.
1971.
Cyanogen bromide fragments of human serum albumin.
J. Biol. Chem.
246:4744-4750[Abstract/Free Full Text].
|
| 11.
|
Meloun, B.,
L. Moravek, and V. Kostka.
1975.
Complete amino acid sequence of human serum albumin.
FEBS Lett.
58:134-137[Medline].
|
| 12.
|
Merritt, K., and N. J. Jacobs.
1976.
Improved medium for detecting pigment production by group B streptococci.
J. Clin. Microbiol.
4:379-380[Abstract/Free Full Text].
|
| 13.
|
Merritt, K., and N. J. Jacobs.
1978.
Characterization and incidence of pigment production by human clinical group B streptococci.
J. Clin. Microbiol.
8:105-107[Abstract/Free Full Text].
|
| 13a.
| Molecular Biology Server. 1999. Sequences.
[Online.] Swiss Institute of Bioinformatics.
http://expasy.hcuge.ch/. [16 February 1999, last date
accessed.]
|
| 14.
|
Moss, C. W., and M. L. Speck.
1966.
Identification of nutritional components in Trypticase responsible for recovery of Escherichia coli injured by freezing.
J. Bacteriol.
91:1098-1104[Abstract/Free Full Text].
|
| 15.
|
Rosa-Fraile, M.,
A. Sampedro,
A. Ruiz-Bravo,
S. Sanbonmatsu, and G. Gimenez-Gallego.
1996.
Identification of serum and urine proteins responsible for enhanced pigment production by group B streptococci as amylases.
Clin. Diagn. Lab. Immunol.
3:594-596[Abstract].
|
| 16.
|
Ruoff, K. L.
1995.
Streptococcus, p. 299-314.
In
P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
|
| 17.
|
Schägger, H., and G. von Jagow.
1987.
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.
Anal. Biochem.
166:368-379[Medline].
|
| 18.
|
Schuchat, A.
1998.
Epidemiology of group B streptococcal disease in the United States: shifting paradigms.
Clin. Microbiol. Rev.
11:497-513[Abstract/Free Full Text].
|
| 19.
|
Sullivan, N. M.
1992.
Culture media development: nutritional growth and metabolic requirements as affected by other factors.
Clin. Microbiol. Newsl.
14:9-14.
|
| 20.
|
Tapsall, J. W.
1986.
Pigment production by Lancefield group B streptococci (Streptococcus agalactiae).
J. Med. Microbiol.
21:75-81[Abstract/Free Full Text].
|
| 21.
|
Wessel, M. R., and D. L. Kasper.
1998.
Group B Streptococcus, p. 1731-1736.
In
S. L. Gorbach, J. G. Bartlett, and N. R. Blacklow (ed.), Infectious diseases, 2nd ed. W. B. Saunders Co., Philadelphia, Pa.
|
Clinical and Diagnostic Laboratory Immunology, May 1999, p. 425-426, Vol. 6, No. 3
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.